
Evergreen Nephrology raises a $130 million round
The Nashville-based company will use the capital to expand into new regions while implementing advanced technologies to improve clinical outcomes.
Evergreen Nephrology, the Nashville-based leader in value-based kidney care, announced that the company has raised $130 million in capital to expand its care model to more patients living with kidney disease.
The round was led by Rubicon Founders, Oak HC/FT, and a group of existing investors, with the addition of K2 HealthVentures. The new funding will fuel Evergreen’s growth by enabling its expansion into new regions while implementing advanced technologies to improve clinical outcomes, streamline care delivery, and ease the administrative burden on nephrologists.
With over 37 million Americans living with chronic kidney disease and Medicare spending exceeding $95 billion annually, Evergreen’s value-based care approach addresses a critical need to transform how kidney disease is managed.
“This investment enables us to broaden access to care programs that improve patient outcomes while driving down healthcare costs,” said John Donlan, Chief Executive Officer of Evergreen Nephrology. “We are dedicated to creating lasting, positive change for patients and families affected by chronic kidney disease.”
Evergreen currently operates across 24 states with a network of more than 900 providers.
Like what you've read?
Forward to a friend!